ALKS 5461 FDA Approval Status
FDA Approved: No
Brand name: ALKS 5461
Generic name: buprenorphine and samidorphan
Company: Alkermes, Inc.
Treatment for: Depression
ALKS 5461 (buprenorphine and samidorphan) is a novel opioid modulator, combining a partial opioid agonist with an opioid antagonist to rebalance brain function in patients with treatment-resistant depression.
Development timeline for ALKS 5461
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.